Zacks Research Estimates Clorox's FY2025 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX - Free Report) - Analysts at Zacks Research dropped their FY2025 earnings per share estimates for Clorox in a research note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $7.09 for the year, down from their prior estimate of $7.15. The consensus estimate for Clorox's current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox's Q4 2026 earnings at $2.11 EPS and FY2027 earnings at $7.34 EPS.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter last year, the business earned $1.71 earnings per share. The firm's revenue for the quarter was down 8.0% on a year-over-year basis.

A number of other brokerages have also issued reports on CLX. UBS Group reduced their target price on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. DA Davidson reduced their price objective on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Wells Fargo & Company dropped their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley reduced their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Barclays dropped their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a report on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Clorox presently has an average rating of "Hold" and an average price target of $151.23.

Clorox Trading Down 2.7%

NYSE CLX opened at $131.90 on Thursday. Clorox has a 12-month low of $127.60 and a 12-month high of $171.37. The company has a fifty day simple moving average of $140.26 and a two-hundred day simple moving average of $152.82. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The stock has a market cap of $16.26 billion, a P/E ratio of 36.04, a P/E/G ratio of 2.62 and a beta of 0.60.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were given a dividend of $1.22 per share. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 annualized dividend and a yield of 3.70%. Clorox's dividend payout ratio is presently 87.61%.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Institutional Trading of Clorox

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Clorox by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company's stock valued at $2,293,135,000 after buying an additional 65,924 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Clorox by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock valued at $501,925,000 after purchasing an additional 69,969 shares during the period. Stifel Financial Corp increased its stake in Clorox by 0.4% during the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock worth $380,761,000 after buying an additional 9,582 shares in the last quarter. Norges Bank purchased a new position in shares of Clorox in the fourth quarter valued at approximately $259,041,000. Finally, Northern Trust Corp lifted its position in shares of Clorox by 2.3% in the first quarter. Northern Trust Corp now owns 1,528,920 shares of the company's stock valued at $225,133,000 after acquiring an additional 34,655 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.